Cell line · CVCL_7759
Papers38
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 38
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| The SMAC-mimetic xevinapant differentially enhances cisplatin and immune checkpoint blockade efficacy in high-risk HPV-positive tumors. | Transl Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hypoxia Induces a Mitotic Survival Advantage After Radiotherapy in Head and Neck Cancer Cells. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genomic Enrichment and Functional Impact of TP53 and CYLD Alterations in Recurrent and Metastatic HPV-Associated Head and Neck Cancer. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting PLK1 Reduces MMP10 to Enhance Radiosensitivity in HPV- Head and Neck Cancer. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| T2R5 Agonist Phendione Decreases Cell Viability and Induces Apoptosis in Head and Neck Squamous Cell Carcinoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic profiling reveals key super-enhancer networks driving oncogenesis in HPV-positive HNSCC. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Splicing of HPV16 E6 promotes aggressive invasion in oropharyngeal cancer via endocytosis of E-cadherin. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting. | Br J Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| In vitro and in vivo validation studies of optimized iron oxide nanoparticles carrying targeting ligands for a new therapeutic strategy in head and neck cancers. | Nanoscale Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Molecular imaging predicts trastuzumab-deruxtecan (T-DXd) response in head and neck cancer xenograft models. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tobacco smoke exposure is a driver of altered oxidative stress response and immunity in head and neck cancer. | J Transl Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 39868226 | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
5-Aza-2'-deoxycytidin (Decitabine) increases cancer-testis antigen expression in head and neck squamous cell carcinoma and modifies immune checkpoint expression, especially in CD39-positive CD8 and CD4 T cells. | Neoplasia | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC. | Front Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Differential Regulation of the STING Pathway in Human Papillomavirus-Positive and -Negative Head and Neck Cancers. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| HPV E6 regulates therapy responses in oropharyngeal cancer by repressing the PGC-1α/ERRα axis. | JCI Insight | 2022 | Its Methods give the RRID and name the line | PubMed | |
| p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade. | Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_7759/papers